Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( SYNCHRONIZE ™‐1)
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70196 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Carel W le Roux und 9 weiteren Autor:innen. Beteiligte Einrichtung: University College Dublin School of Medicine, Dublin, Ireland. Hauptthemen laut MEDLINE: Obesity, Glucagon-Like Peptide-1 Receptor Agonists, Anti-Obesity Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Aims
Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report the baseline characteristics of participants in the SYNCHRONIZE‐1 trial in adults with obesity without T2D ( ClinicalTrials.gov : NCT06066515). Materials and methods Participants aged ≥18 years with BMI ≥30 or ≥27 kg/m 2 with ≥1 obesity complication without T2D were randomized 1:1:1 to double‐blind, once‐weekly, subcutaneous injections of survodutide (up‐titrated to 3.6 or 6.0 mg) or placebo for 76 weeks. The primary endpoints are percent body weight change and achievement of body weight reduction ≥5% from baseline to Week 76. Efficacy and safety analyses will include all randomized and treated participants.
Results
At baseline, participants ( n = 725 from 14 countries) had a mean age of 47.1 years, BMI 37.9 kg/m 2 , and waist circumference 115.2 cm. Most participants (59.4%) were female; 47.3% were from North America, 21.0% from Europe, and 20.0% from East Asia. Obesity complications included hypertension (40.0%), dyslipidaemia (33.7%), and prediabetes (30.2%). Mean haemoglobin A1c was 5.5%, estimated glomerular filtration rate 93.0 mL/min/1.73 m 2 , systolic/diastolic blood pressure 127.0/82.7 mmHg, and low‐density lipoprotein cholesterol 116.4 mg/dL; 21.8% were taking lipid‐lowering drugs.
Conclusions
SYNCHRONIZE‐1 will determine the efficacy, safety, and tolerability of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for weight loss in a representative cohort of people with obesity without T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University College Dublin School of Medicine, Dublin, Ireland.
- Ulster University, Coleraine, UK.
- McMaster University, Hamilton, Ontario, Canada.
- University of Toronto, Toronto, Ontario, Canada.
- Winters Center for Heart Failure Research, Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA.
- Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Carel W le Roux, Sean Wharton, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Lee M Kaplan
Förderung
- Boehringer Ingelheim
Zitieren
APA
le Roux, C. W., Wharton, S., Bozkurt, B., Platz, E., Bleckert, G., Ajaz Hussain, S., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2026). Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( SYNCHRONIZE ™‐1). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70196
Vancouver
le Roux CW, Wharton S, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, et al. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( SYNCHRONIZE ™‐1). Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70196
BibTeX
@article{leRoux2026,
author = {le Roux, Carel W and Wharton, Sean and Bozkurt, Biykem and Platz, Elke and Bleckert, Gabriele and Ajaz Hussain, Samina and Brueckmann, Martina and Startseva, Elena and Kloer, Isabel M and Kaplan, Lee M},
title = {Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( SYNCHRONIZE ™‐1)},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70196}
}
EUVIMED